Navigation Links
Moffitt Cancer Center instrumental in new clinical guidelines for cancer-related fatigue
Date:5/30/2014

TAMPA, Fla. (May 30, 2014) Fatigue is a debilitating problem for cancer patients undergoing treatment; however, it also poses a huge detriment after treatment and can significantly affect quality of life. Approximately 30 percent of cancer patients endure persistent fatigue for several years after treatment, according to an American Society of Clinical Oncology Expert Panel co-chaired by Paul Jacobsen, Ph.D., associate center director of Population Sciences at Moffitt Cancer Center.

ASCO created the panel to develop assessment, screening, and treatment guidelines for medical professionals to help patients who experience fatigue after completing primary treatment. The panel analyzed several national guidelines from the United States and Canada, and reviewed published studies about cancer-related fatigue to create the new guidelines.

The panel recommends that all health care professions regularly screen and measure fatigue and other associated problems in cancer patients through health history, physical examinations, and laboratory analysis. It is important for all patients to be educated about fatigue and its associated medical problems.

Fatigue in cancer patients after treatment can arise from other problems, such as depression, pain, anxiety, nutritional deficits, medications, or emotional distress. The panel recommends that all contributing factors should be identified and treated before the symptoms of fatigue are addressed.

There are a number of treatment and care options for patients experiencing continued fatigue. "Studies show that initiating or maintaining adequate levels of physical activity can reduce cancer-related fatigue in post-treatment patients. Physicians should actively encourage all patients to engage in a moderate level of physical activity after cancer treatment, dependent on risk of injury," said Jacobsen.

Behavioral and psychoeducational therapies have also been reported to reduce fatigue in cancer patients. The panel recommends that patients interested in these options be referred to psychosocial service providers who specialize in cancer. Some studies also suggest that yoga, acupuncture and mindfulness-based approaches may also be beneficial.

The panel does not recommend medication to alleviate fatigue in cancer patients after treatment. While some data suggest that medication can help patients suffering from fatigue who have advanced disease or are receiving cancer treatment, there is insufficient evidence that these medications relieve fatigue in patients after treatment.

The new guidelines appeared in the April 14 issue of the Journal of Clinical Oncology.


'/>"/>

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
2. Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy
3. Moffitt instrumental in FDA approval of revolutionary 2-drug combo to treat advanced melanoma
4. Moffitt Cancer Center launches prostate cancer study focused on black men
5. Single injection may revolutionize melanoma treatment, Moffitt study shows
6. Moffitt researchers identify gene variations that may help predict cancer treatment response
7. Moffitt Cancer Center expert standardizing guidelines for penile cancer treatment
8. Protein complex linked to cancer growth may also help fight tumors, Moffitt researchers say
9. Single men, smokers at higher risk for oral human papillomavirus infection, Moffitt study shows
10. How to boost Hispanics participation in clinical trials? Relate to them, Moffitt study shows
11. New screening approach identifies small proteins unique to melanoma cells, Moffitt researcher says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare ... at risk of price gouging for their prescription drugs, according to a new ... Medicare isn’t negotiating on our behalf, there’s no consistency in drug pricing among ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the ... in an average life. This mouse sets out on a journey that will show ... Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “The Financial Favor ... “The Financial Favor of God; Second Edition” is the creation of published author, Brooks ... take this opportunity to talk to you about the financial favor of God. Not ...
(Date:9/19/2017)... York, NY (PRWEB) , ... September 19, 2017 ... ... firm, announced today the addition of strategic marketing leader, Denise Flannery, to its ... Strategic Marketing, Brand and Management Consultant, Denise will work with clients across different ...
(Date:9/19/2017)... Dallas, TX (PRWEB) , ... September 19, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to Texas as a part of its national Swirl: ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...  Eli Lilly and Company (NYSE: ... to more efficiently focus resources on developing new ... workforce reductions, including those from a U.S. voluntary ... 3,500 positions. With the streamlining ... approximately $500 million that will begin to be ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/7/2017)... , Sept. 7, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Healthcare Conference at the Grand Hyatt hotel in New ... 2017 at 11:40 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Medicine Technology: